Table 1 Demographic and clinical characteristics.

From: Circulating cell-free mitochondrial DNA levels and glucocorticoid sensitivity in a cohort of male veterans with and without combat-related PTSD

 

Total (n = 232)

Control (n = 121)

PTSD (n = 111)

p valued

Age (years, mean ± s.d.)

33.44 ± 8.55

33.08 ± 8.61

33.84 ± 8.51

0.503

Education (years, mean ± s.d.)

14.45 ± 2.11

14.96 ± 2.15

13.9 ± 1.94

<0.001

BMI (mean ± s.d.)

28.93 ± 5.00

28.19 ± 4.40

29.72 ± 5.48

0.023

Race/ethnicity

   

0.029

 Non-Hispanic Asian, n (%)

15 (6.5)

11 (9.1)

4 (3.6)

–

 Non-Hispanic Black, n (%)

52 (22.4)

26 (21.5)

26 (23.4)

–

 Non-Hispanic Native American, n (%)

2 (0.9)

2 (1.7)

0 (0)

–

 Non-Hispanic Other, n (%)

7 (3.0)

4 (3.3)

3 (2.7)

–

 Non-Hispanic White, n (%)

75 (32.3)

46 (38.0)

29 (26.1)

–

 Hispanic, n (%)

81 (34.9)

32 (26.4)

49 (44.1)

–

Antidepressant users, n (%)a

35 (15.1)

5 (4.1)

30 (27.0)

<0.001

Smoking Statusb

   

<0.001

 Not at all, n (%)

157 (80.5)

94 (88.7)

63 (70.8)

–

 Some days, n (%)

15 (7.7)

8 (7.5)

7 (7.9)

–

 Every day, n (%)

23 (11.8)

4 (3.8)

19 (21.3)

–

Current CAPS total score (mean ± s.d.)

34.88 ± 34.90

3.83 ± 5.09

68.72 ± 17.69

<0.001

HbA1c (%, mean ± s.d.)

5.40 ± 0.75

5.33 ± 0.47

5.47 ± 0.99

0.766

Participants with Diabetes (HbA1c > 6.5%)c

9

3

6

0.198

  1. BMI body mass index, HbA1c hemoglobin A1c, CAPS Clinician-Administered PTSD Scale.
  2. aData on antidepressant use was not available for 1 participant in the PTSD positive group.
  3. bData on smoking status was not available for 37 participants (PTSD negative: n = 15; PTSD positive: n = 22).
  4. cData on HbA1c was not availalble for 9 participants in the PTSD positive group.
  5. dFor continuous variables, a t-test was used. For categorical variables, a χ2 test was used.
Back to article page